Market Research Logo

Global Post Menopausal Vaginal Atrophy Drugs Market 2016-2020

About Post-Menopausal Vaginal Atrophy Drugs

Vaginal atrophy also known as atrophic vaginitis is defined as a decrease in the production of estrogen after menopause, leading to thinning, drying, and reduced elasticity of the vaginal tissues. Up to 40% of post-menopausal women have symptoms of atrophic vaginitis. It typically affects women in the age group of 45-55 years. PVA result in symptoms such as itching, burning, dryness, and dyspareunia. Topical preparations such as hormone replacement therapy (HRT) and estrogen creams are used to treat PVA.

Technavio’s analysts forecast the global PVA drugs market to grow at a CAGR of 7.13% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global PVA drugs market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of drugs (creams, tablets, patches, and rings) used to treat PVA.

The market is divided into the following segments based on geography:

  • Americas
  • EMEA
  • APAC
Technavio's report, Global Post-Menopausal Vaginal Atrophy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Pfizer Inc.
  • Allergan Inc.
  • Shionogi & Co. Ltd.
  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Ltd.
Other prominent vendors
  • Bayer
  • Bionovo
  • EndoCeutics
  • Foamix Pharmaceuticals
  • Ligand Pharmaceuticals
  • Pantarhei Bioscience
  • Pep-Tonic Medical
  • TherapeuticsMD
  • Upsher-Smith Laboratories
Market driver
  • Favorable healthcare reforms in the US
  • For a full, detailed list, view our report
Market challenge
  • Patent expiry of branded products
  • For a full, detailed list, view our report
Market trend
  • Paradigm shift to non-estrogenic therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Post-Menopausal Vaginal Atrophy Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the Global Post-Menopausal Vaginal Atrophy Drugs Market: Pfizer Inc., Allergan Inc., Shionogi & Co. Ltd., Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd.

Other Prominent Vendors in the market are: Bayer, Bionovo, EndoCeutics, Foamix Pharmaceuticals, Ligand Pharmaceuticals, Pantarhei Bioscience, Pep-Tonic Medical, TherapeuticsMD, and Upsher-Smith Laboratories.

Commenting on the report, an analyst from Technavio’s team said: “Non-estrogenic therapies in PVA treatment are a paradigm shift from systemic estrogen therapies such as creams, patches, and gels. In addition, the launch of late-stage pipeline products is expected to shift the attention from vaginal creams and OTC classes toward vaginal tablets and oral therapies. For instance, the recent launch of two non-estrogenic therapies with improved safety profiles, Osphena by Shionogi and BZA/CE by Bayer, will allow manufacturers to tap a large pool of untreated people. ”

According to the report, the Affordable Care Act has increased the number of insured women and has been a driving factor in the treatment-seeking behavior of people with this condition. The law puts in place comprehensive health insurance reforms that will roll out over four years and beyond. This provides Americans with better health security by putting in place comprehensive health insurance reforms that lower healthcare costs and expand the coverage.

Further, the report states that the market is currently served by generic products due to the patent expiries of branded products such as Premarin, which lost its patent in 2012. The patent of Colpotrophine also expired in 2015. Patent expiries will lead to the entry of generic versions of the particular drugs in the market, resulting in the sales erosion of branded products. This will result in heavy financial loss to the parent drug makers.

Companies Mentioned

Pfizer Inc., Allergan Inc., Shionogi & Co. Ltd., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Bayer, Bionovo, EndoCeutics, Foamix Pharmaceuticals, Ligand Pharmaceuticals, Pantarhei Bioscience, Pep-Tonic Medical, TherapeuticsMD, Upsher-Smith Laboratories.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
    • Assumptions
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Key buying criteria
      • Table Key buying criteria for PVA drugs
  • Overview: Vaginal atrophy
    • Symptoms
      • Table Symptoms of PVA
      • Table Percentage of major vaginal atrophy symptoms in postmenopausal women
    • Causes
      • Table Causes of PVA
    • Pathophysiology
      • Table Effects of estrogen deficiency
    • Diagnosis
    • Treatment
      • Table Treatment for PVA
      • Table Some hormonal treatments for PVA
      • Table Top concerns associated with OTC lubricants or moisturizers for PVA
      • Table Top concerns about use of vaginal estrogen for PVA
    • Epidemiology
      • Table Prevalence of vaginal atrophy symptoms in postmenopausal women by country 2014
  • Branded drug profiles
    • Activella
    • Enjuvia
    • Estrace
    • Femring
    • Premarin
    • Osphena
    • Vagifem
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global PVA drugs market 2015-2020 ($ billions)
      • Table Five forces analysis
  • Market segmentation by drug class
    • Table Global PVA drugs market segmentation by drug class
    • Topical estrogen
    • Systemic estrogen
      • Table Global PVA drugs market share by drug class
      • Table Preference for oral or vaginal ROA by age 2014
  • Geographical segmentation
    • Global PVA drugs market by geographical segmentation 2015-2020
      • Table Global PVA drugs market by geography 2015
      • Table Global PVA drugs market revenue by geography 2015-2020 ($ millions)
      • Table Global PVA drugs market: YoY revenue and growth based on geography 2015-2020 ($ millions)
    • PVA drugs market in Americas
      • Table PVA drugs market in Americas 2015-2020 ($ billions)
      • Table PVA drugs market in Americas by country 2015
    • PVA drugs market in US
      • Table PVA drugs market in US 2015-2020 ($ billions)
      • Table Share of PVA drugs in US by drug class 2015
    • PVA drugs market in EMEA
      • Table PVA drugs market in EMEA 2015-2020 ($ millions)
      • Table PVA drugs market in EMEA by region 2015
    • PVA drugs market in Europe
      • Table PVA drugs market in Europe 2015-2020 ($ millions)
      • Table Share of PVA drugs in Europe by drug class 2015
    • PVA drugs market in APAC
      • Table PVA drugs market in APAC 2015-2020 ($ millions)
      • Table PVA drugs market in APAC by country 2015
    • PVA drugs market in Japan
      • Table PVA drugs market in Japan 2015-2020 ($ millions)
      • Table Share of PVA drugs in Japan by drug class 2015
  • Market drivers
    • Significant unmet medical needs
    • Favorable healthcare reforms in US
    • Increase in awareness of PVA
    • Cost-effective OTC drugs
      • Table Specific OTC treatments for vaginal atrophy
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Patent expiry of branded products
    • Low diagnosis rates
    • Poor patient adherence
    • Side effects of drugs
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Paradigm shift to non-estrogenic therapies
    • Increased R&D
    • Patient assistance programs
    • Strategic alliances
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2015
      • Table Global PVA drugs market share analysis 2015
      • Table Market share analysis of top vendors 2015
    • Pfizer
      • Table Timeline and history of Premarin
      • Table Pfizer: YoY revenue and growth rate of Premarin 2013-2015 ($ billions)
      • Table Pfizer: Geographical segmentation of Premarin 2015
      • Table Pfizer: Key takeaways
    • Allergan
      • Table Allergan: YoY revenue and growth rate of Estrace 2013-2015 ($ millions)
      • Table Allergan: Key takeaways
    • Shionogi
      • Table YoY revenue comparison of Osphena 2013 and 2014 ($ millions)
      • Table Shionogi: Key takeaways
    • Novo Nordisk
      • Table Novo Nordisk: Key takeaways
    • Teva Pharmaceutical
      • Table Timeline for Enjuvia
      • Table Teva Pharmaceutical: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report